Peptide-Major Histocompatibility Complex - T-cell receptor interaction (pMHC-TCR interaction)

The interaction between the Peptide-Major Histocompatibility Complex (pMHC) and the T-cell receptor (TCR) is the fundamental mechanism of the adaptive immune system. Autologous dendritic cells (DCs) function as professional antigen-presenting cells that capture, process, and display antigenic peptides on their surface via MHC molecules [UniProt, 2024]. When these pMHC complexes bind to a specific TCR on a patient's T cells, they initiate a signaling cascade that triggers T-cell activation, proliferation, and differentiation into effector cells [PubMed, 2022]. This biological process is the primary target of dendritic cell-based immunotherapies, such as Sipuleucel-T, which are designed to prime the immune system against specific tumor-associated antigens [FDA, 2020]. By loading a patient's own DCs with antigens ex vivo, clinicians can enhance the frequency and potency of this interaction to treat various malignancies and chronic infections [Nature Reviews Cancer, 2021]. However, the therapeutic success of targeting this interaction depends heavily on the presence of co-stimulatory signals and the ability to overcome the immunosuppressive environment often found in tumors.

Other names

Antigen-MHC complexT-cell receptor-ligand interactionImmune synapseDendritic cell-T cell interactionpMHC-TCR complex

Activation of antigen-specific T-cells through the presentation of tumor-associated or viral antigens by dendritic cells to the T-cell receptor, leading to a targeted cytotoxic immune response [NCI, 2023].